source
- Novo Nordisk CFO describes roller-coaster growth and stays optimistic about CagriSema after Q2 earningsNovo Nordisk CFO Karsten Munk Knudsen talked to Fierce after the company released its second-quarter earnings, reflecting on his nine-year tenure and the firm’s volatile performance. He recalled a…
- Attovia Therapeutics raises $289 million in IPO to fund anti-itch drug developmentAttovia Therapeutics completed an initial public offering that generated $289 million in gross proceeds. The company sold 17 million shares at $17 each, exceeding its original target of $182.4 mill…